Article Text

Download PDFPDF
DI-017 Usage profile, effectiveness and safety of coformulated Rilpivirine/Emtricitabine/Tenofovir
  1. J Fernandez Martin,
  2. JA Morales Molina,
  3. A Martos Rosa,
  4. A Fayet Pérez,
  5. J Urda Romacho,
  6. D González Vaquero,
  7. M Gimeno Jordá
  1. Apes Hospital Poniente, Pharmacy, El Ejido, Spain

Abstract

Background Rilpivirine/Emtricitabine/Tenofovir (RPV/FTC/TDF) is a single tablet regimen recommended for treatment-naïve HIV patients with baseline viral load (VL) < 100.000 copies/mL.1

Purpose To analyse the usage profile, effectiveness and safety of RPV/FTC/TDF.

Material and methods Retrospective study conducted in a Primary Hospital between May 2013–Sept 2014. Patients included were those with HIV infection who started RPV/FTC/TDF treatment. Data were collected from electronic medical records: Demographics, previous antiretroviral therapy (ART), reason for treatment, immunovirological status, laboratory data (VL, CD4, c-LDL, Total Cholesterol) and adverse effects before/after start of RPV/FTC/TDF. Adherence was assessed by the dispensing records and the Simplified Medication Adherence Questionnaire (SMAQ) (patients were considered adherent with scores over 95%).

Results RPV/FTC/TDF was initiated in 21/390 (5%) patients with ART. Age (years): 45 (range: 31–70); Male: 14/21 (68%). Patients with previous ART: EFV/FTC/TDF: 7; FTC/TDF/ATV/r: 2; 3TC/AZT/NVP: 1; 3TC/AZT/LPV/r: 1; ABC/AZT/LPV/r: 1; TDF/FTC/NVP: 1; FTC/TDF/ETV: 1; FTC/TDF/DRV/r: 1; DRV/r: 1; FTC/TDF: 1. Reasons for prescription: 17 ART-experienced (81%) and 4 ART-naïve (19%). Pretreated reasons: 9 (53%) simplifications, 6 (36%) to avoid previous ART toxicity (EFV: 4, Protease Inhibitors: 2) and 2 (11%) others. Three patients were withdrawn (low adherence: 2, pantoprazole interaction: 1). Pre-treatment data: Adherence > 95% 7/17 (41%), VL < 50 copies/mL: 8/21 (38%), pretreated VL < 50 copies/mL: 8/17 (47%), CD4: 507, c-LDL: 114 mg/dL, Total cholesterol: 180 mg/dL. Post-treatment data: Adherence > 95%: 17/21 (80%), patients simplified to RPV/FTC/TDF who achieved >95% adherence: 6/9 (66%), VL < 50 copies/mL: 18/21 (85%), pretreated VL < 50 copies/mL: 16/17 (94%), CD4: 563, c-LDL: 102 mg/dL, Total cholesterol: 164 mg/dL. Reduction in c-LDL and Total Cholesterol was 10% and 9% respectively, which is consistent with previous studies.2 Only one patient experienced headaches during the first week with RPV/FTC/TDF.

Conclusion RPV/FTC/TDF was used primarily as a strategy for simplification and to avoid ART toxicity, mainly due to EFV. All patients had undetectable VL, improved adherence (+39%), effectiveness (11% increase in CD4) and treatment was well tolerated. Lipid profile was improved too.

References

  1. EACS Guidelines Version 7.02. June 2014

  2. Sharma M, Saravolatz LD. J Antimicrob Chemothe 2013;(68):250–6

ReferencesNo conflict of interest.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.